HC Wainwright Issues Positive Estimate for Nuvalent Earnings

Nuvalent, Inc. (NASDAQ:NUVL - Free Report) - HC Wainwright upped their FY2026 earnings estimates for Nuvalent in a research report issued to clients and investors on Tuesday, June 24th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($3.19) per share for the year, up from their prior estimate of ($3.24). HC Wainwright currently has a "Buy" rating and a $130.00 target price on the stock. The consensus estimate for Nuvalent's current full-year earnings is ($3.86) per share. HC Wainwright also issued estimates for Nuvalent's Q4 2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.12) EPS, FY2028 earnings at $2.96 EPS and FY2029 earnings at $7.50 EPS.

Several other research analysts also recently commented on NUVL. UBS Group upgraded shares of Nuvalent from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research report on Friday, March 14th. Leerink Partners boosted their price objective on shares of Nuvalent from $125.00 to $140.00 and gave the company an "outperform" rating in a research report on Tuesday. Wedbush restated an "outperform" rating and set a $115.00 price objective on shares of Nuvalent in a research report on Tuesday. Finally, Robert W. Baird boosted their price objective on shares of Nuvalent from $105.00 to $112.00 and gave the company an "outperform" rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Nuvalent currently has an average rating of "Moderate Buy" and a consensus price target of $119.60.

Nuvalent Trading Up 2.9%

NASDAQ NUVL opened at $79.09 on Thursday. Nuvalent has a 1-year low of $55.54 and a 1-year high of $113.51. The company has a 50 day moving average of $74.42 and a 200-day moving average of $76.53. The company has a market cap of $5.68 billion, a price-to-earnings ratio of -18.02 and a beta of 1.34.

Nuvalent (NASDAQ:NUVL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.18) earnings per share for the quarter, missing analysts' consensus estimates of ($1.14) by ($0.04). During the same quarter in the prior year, the business posted ($0.69) EPS.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NUVL. Voya Investment Management LLC grew its stake in shares of Nuvalent by 6.6% in the first quarter. Voya Investment Management LLC now owns 120,311 shares of the company's stock worth $8,532,000 after purchasing an additional 7,414 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Nuvalent by 5.1% in the first quarter. Rhumbline Advisers now owns 53,026 shares of the company's stock worth $3,761,000 after purchasing an additional 2,572 shares during the last quarter. Strs Ohio bought a new stake in shares of Nuvalent in the first quarter worth $404,000. Intech Investment Management LLC grew its stake in shares of Nuvalent by 28.7% in the first quarter. Intech Investment Management LLC now owns 19,262 shares of the company's stock worth $1,366,000 after purchasing an additional 4,293 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Nuvalent by 8.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,941 shares of the company's stock worth $10,634,000 after purchasing an additional 12,123 shares during the last quarter. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Nuvalent

In other news, CEO James Richard Porter sold 27,000 shares of the company's stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $68.94, for a total transaction of $1,861,380.00. Following the completion of the transaction, the chief executive officer now directly owns 249,062 shares in the company, valued at approximately $17,170,334.28. This represents a 9.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.20% of the company's stock.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.